# Loreline Study: Characterization of Long Responders Under Eribuline

> **NCT03771183** · — · COMPLETED · sponsor: **Centre Jean Perrin** · enrollment: 97 (actual)

## Conditions studied

- Breast Cancer Patients
- Therapy Related Tumor

## Interventions

- **OTHER:** Patients in long response during Halaven® treatment

## Key facts

- **NCT ID:** NCT03771183
- **Lead sponsor:** Centre Jean Perrin
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-23
- **Primary completion:** 2020-11-30
- **Final completion:** 2021-02-28
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2021-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03771183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03771183, "Loreline Study: Characterization of Long Responders Under Eribuline". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03771183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*